Entering text into the input field will update the search result below

BioLine (BLRX -51%) craters after discontinuing Phase II/III Clarity trials for its...

Mar. 20, 2013 12:10 PM ETBioLineRx Ltd. (BLRX) StockBLRXBy: David Yelle, SA News Editor
BioLine (BLRX -51%) craters after discontinuing Phase II/III Clarity trials for its antipsychotic-drug BL-1020, saying it wasn't effective when compared with the antipsychotic Risperidone, its primary efficacy endpoint. The company plans to complete its analysis of the data to determine if there may be future potential for the product. As a result of the discontinuation, the company expects to incur a $6M to $7M reduction in planned R&D expenses for the rest of 2013 and part of 2014.

Recommended For You

More Trending News

About BLRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BLRX--
BioLineRx Ltd.